These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 36988669)

  • 1. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
    Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
    Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Alleva DG; Delpero AR; Scully MM; Murikipudi S; Ragupathy R; Greaves EK; Sathiyaseelan T; Haworth JR; Shah NJ; Rao V; Nagre S; Lancaster TM; Webb SS; Jasa AI; Ronca SE; Green FM; Elyard HA; Yee J; Klein J; Karnes L; Sollie F; Zion TC
    Vaccine; 2021 Oct; 39(45):6601-6613. PubMed ID: 34642088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
    Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response.
    Liu Z; Yang C; Zhang H; Cao G; Wang S; Yin S; Wang Y
    Front Immunol; 2022; 13():960094. PubMed ID: 36389744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
    J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.
    Liu Z; Zhou J; Xu W; Deng W; Wang Y; Wang M; Wang Q; Hsieh M; Dong J; Wang X; Huang W; Xing L; He M; Tao C; Xie Y; Zhang Y; Wang Y; Zhao J; Yuan Z; Qin C; Jiang S; Lu L
    Cell Res; 2022 Mar; 32(3):269-287. PubMed ID: 35046518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
    Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
    EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
    Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
    PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
    Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
    J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
    Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
    Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
    Front Immunol; 2022; 13():974364. PubMed ID: 36159845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.
    Chang TY; Li CJ; Chao TL; Chang SY; Chang SC
    Appl Microbiol Biotechnol; 2024 Oct; 108(1):486. PubMed ID: 39412657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.